Using enzyme-linked immunosorbent assay (ELISA), it was shown that sHLA-E was presented in healthy donors, but its level was relatively higher in plasma samples of patients with melanoma [57], neuroblastoma [58], and chronic lymphocytic leukemia [59] on advanced disease stage. The gene discussed is HLA-E; the disease is melanoma.